Drug-resistant cells are often metabolically inactive, compromising the suitability of mostly used drug response assays on organoids. In this publication @Cell reports, we designed a novel microscopy-based drug screen that accurately distinguishes dead from alive organoids. We found microtubule-targeting agents, commonly used in clinical oncology, to eliminate RAS mutant cells resistant to effective MAPK pathway inhibition.
Superior work from Sander!!! now being tested in a clinical trial!!!